Skip to main content

Advertisement

Table 2 Comparing the motor nerve conduction measurements between the two study groups

From: The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial

  n-3 PUFAs (Mean ± SD) Placebo (Mean ± SD) Mean Difference 95 % CI, P-value
Tibial nerve     
DML 1 (ms) 4.82 ± .81 5.80 ± 1.31 −.98 −1.50 to −.46, <.001*
DML 2a 4.60 ± .79 5.70 ± .95 − .68 − 1.18 to −.17, .009**
% Changec − 4.77 − 1.73   
a-CMAP1(mV) 9.30 (5.62–13.72) 10.20 (5.60–15.30) -- .696***
a-CMAP 2 10.20 (6.20–13.00) 6.10 (3.47–9.25)   .003b
% Change 9.68 − 40.20   
MCV 1(m/s) 45.81 ± 6.61 43.06 ± 5.08 2.74 −.05 to 5.54, .054*
MCV 2 45.67 ± 6.18 42.34 ± 4.68 1.86 − .52 to 4.25, .123**
% Change −.31 − 1.70   
Peroneal nerve     
DML 1 (ms) 4.34 ± .92 5.21 ± 1.44 −.87 −1.45 to −.30, .004*
DML 2 4.16 ± 1.04 5.02 ± 1.95 .08 − .78 to .94, .850**
% Change − 3.93 − 3.65   
a-CMAP1(mV) 4.00 (3.00–4.60) 2.80 (1.90–5.20) -- .238***
a-CMAP 2 4.40 (3.10–5.30) 2.90 (1.17–4.75)   .217b
% Change 10.00 3.57   
MCV 1(m/s) 47.59 ± 5.95 44.07 ± 6.91 3.51 .40 to 6.63, .028*
MCV 2 44.70 ± 5.30 43.60 ± 6.87 − 1.37 − 3.88 to 1.14, .278**
% Change − 6.07 −1.07   
Ulnar nerve     
DML 1 (ms) 3.12 ± .61 3.35 ± .59 −.23 −.51 to .060, .118*
DML 2 2.97 ± .55 3.33 ± .59 − .26 − .54 to .02, .073**
% Change − 4.81 − .60   
aCMAP1(mV) 11.85 (9.40–14.30) 12.40 (10.80–13.10) -- .394***
a-CMAP 2 13.10 (10.10–15.00) 10.75 (10.00–13.60)   .033b
% Change 10.55 − 13.31   
MCV 1(m/s) 63.01 ± 26.22 55.60 ± 10.89 7.42 −2.14 to 16.98, .126*
MCV 2 53.64 ± 16.72 53.98 ± 6.34 .07 −6.84 to 6.97, .984**
% Change − 14.87 − 2.90   
  1. DML distal motor latency, a-CMAP amplitude of compound muscle action potential, MCV motor conduction velocity
  2. *P value is reported based on Independent-Samples T-Test
  3. **P value is reported based on the analysis of covariance, adjusted for baseline values
  4. ***P value is reported based on the Mann–Whitney U Test
  5. aOne month after the cessation of chemotherapy
  6. b P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
  7. cPercent change in proportion to the baseline values